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Introduction
The severity of  acute COVID-19 is attributable to genetics, immune dysregulation, abnormal blood clotting 
and tissue disruption, particularly implicating aberrant proinflammatory and antiviral innate immunity (1–
14). Rheumatoid arthritis (RA) represents a proinflammatory cytokine–driven chronic articular condition 
often accompanied by interstitial lung disease and alveolitis (15). We (16) and others (17) have reported that 
We explored the potential link between chronic inflammatory arthritis and COVID-19 pathogenic 
and resolving macrophage pathways and their role in COVID-19 pathogenesis. We found that 
bronchoalveolar lavage fluid (BALF) macrophage clusters FCN1+ and FCN1+SPP1+ predominant 
in severe COVID-19 were transcriptionally related to synovial tissue macrophage (STM) clusters 
CD48hiS100A12+ and CD48+SPP1+ that drive rheumatoid arthritis (RA) synovitis. BALF macrophage 
cluster FABP4+ predominant in healthy lung was transcriptionally related to STM cluster TREM2+ that 
governs resolution of synovitis in RA remission. Plasma concentrations of SPP1 and S100A12 (key 
products of macrophage clusters shared with active RA) were high in severe COVID-19 and predicted 
the need for Intensive Care Unit transfer, and they remained high in the post–COVID-19 stage. High 
plasma levels of SPP1 were unique to severe COVID-19 when compared with other causes of severe 
pneumonia, and IHC localized SPP1+ macrophages in the alveoli of COVID-19 lung. Investigation into 
SPP1 mechanisms of action revealed that it drives proinflammatory activation of CD14+ monocytes 
and development of PD-L1+ neutrophils, both hallmarks of severe COVID-19. In summary, COVID-19 
pneumonitis appears driven by similar pathogenic myeloid cell pathways as those in RA, and their 
mediators such as SPP1 might be an upstream activator of the aberrant innate response in severe 
COVID-19 and predictive of disease trajectory including post–COVID-19 pathology.
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SARS-CoV-2 infection is associated with emergence of  polyarthritis, or flares of  synovitis in RA patients in 
sustained disease remission, suggesting shared mechanisms of  pathogenesis. RA immunopathogenesis and 
therapeutic targets (18) are well understood and might be informative for COVID-19 therapeutic strategies. 
In RA, articular inflammation and remission are driven by distinct synovial tissue macrophage clusters (19). 
Emerging data suggest that similar aberrant activation of  myeloid cells in the blood (7, 20–23) and lung (24, 
25) contribute to acute COVID-19 severity. However, there remains a knowledge gap on myeloid cell path-
ways that determine the severity and resolution of  acute COVID-19 pneumonitis. In addition, the immune 
mechanisms of  long-lasting clinical sequelae (26) described in convalescent COVID-19 patients are unre-
solved, hindering development of  effective treatments and biomarkers of  disease trajectory.
Single-cell profiling and fate-mapping indicate spatial and functional macrophage heterogeneity that 
maintains lung homeostasis (27–31). Healthy lung alveolar macrophages (AM) expressing Fatty Acid Bind-
ing Protein 4 (FABP4) localize to the alveolar epithelial surface and recycle surfactants with type-2 alveolar 
epithelial cells to maintain compliance and efficient gas exchange (32, 33). This function is compromised 
in severe COVID-19 (34). The single-cell RNA sequencing (scRNAseq) analysis (24) of  bronchoalveolar 
lavage fluid (BALF) from severe COVID-19 patients found abnormally low numbers of  resident AM and 
an increase in 2 macrophage clusters that share expression of  ficolin-1 (FCN1) and are distinguished by 
their relative expression of  osteopontin (SPP1): FCN1+ and FCN1+SPP1+ clusters. Their precise roles in 
the pathogenesis of  severe COVID-19 have yet to be established. We recently identified similar macrophage 
diversity in synovial tissues (ST) of  healthy donors and patients with active or remission RA (19). We delin-
eated in RA chronic synovitis that the CD48hiS100A12+ and CD48+SPP1+ macrophage clusters produced 
their distinctive pathogenic mediators (S100A12 and SPP1, respectively) in addition to hallmark proinflam-
matory cytokines IL-6, IL-8, IL-1β, and TNF-α, and activated ST stromal cells. Early evidence suggested 
that this serum IL-6, IL-8, IL-1β, and TNF-α cytokine signature also predicts the prognosis of  patients with 
acute COVID-19 (6), and targeting the IL-6 pathway seems an effective therapeutic strategy in critically ill 
COVID-19 patients (35, 36). Resolution of  synovitis in RA was associated with the functions of  a distinct 
subpopulation of  synovial macrophages (TREM2+ and FOLR2+ clusters) that produced abundant lipid 
resolvins instead of  inflammatory mediators and induced a repair phenotype in ST stromal cells (19). 
Altogether, this raised the hypothesis that macrophage clusters in the lung, functionally equivalent to those 
in the synovium, may govern chronic inflammation or resolution of  COVID-19 pneumonitis, and that the 
hallmark cytokine signature related to these clusters (e.g., SPP1) might be a useful biomarker of  prognosis 
and a therapeutic target during the unpredictable trajectory of  COVID-19.
Results
COVID-19 BALF FCN1+ and FCN1+SPP1+ macrophage clusters are transcriptionally similar to CD48hiS100A12+ and 
CD48+SPP1+ clusters that drive RA synovitis. In COVID-19 BALF, Liao et al. (24) identified 4 major clusters 
of  macrophages characterized by a combination of  expression of  SPP1, FCN1, and FABP4. Importantly, 
expansion of  the FCN1+ and FCN1+SPP1+ clusters was indicative of  COVID-19 severity (Supplemental 
Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.147413DS1). Among the 9 phenotypically distinct clusters of  ST macrophages (STMs) that dif-
fered in distribution between healthy donors and patients with RA, the CD48hiS100A12+ and CD48+SPP1+ 
clusters were expanded in RA patients with active disease (Supplemental Figure 1, C and D) (19). To test 
the relationship between COVID-19 BALF and RA STM clusters, we integrated the macrophage scRNA-
seq data sets from COVID-19 BALF (GSE145926; Supplemental Figure 1, A and B) (24) and our RA ST 
(E-MTAB-8322; Supplemental Figure 1, C and D) (19) using Seurat V3 anchor integration strategy (37). 
The dimensional reduction of  integrated macrophage data sets illustrated by Uniform Manifold Approxi-
mation and Projection (UMAP) visualize overlapping and tissue-specific macrophage clusters (Figure 1, A 
and B). To investigate the relationship between these macrophage clusters from synovitis and pneumonitis, 
hierarchical clustering (Figure 1C) was performed on the matrix of  the average expression of  each ST and 
BALF cluster of  all 8902 genes that were common to both data sets. The hierarchical clustering dendro-
gram illustrating the relationship between the clusters by branch point (split) and branch length (distance) 
revealed that the macrophage clusters were separated predominantly by their precursor origin and func-
tion — i.e., embryonic-origin (homeostasis) or monocyte-derived (inflammation) rather than source tissue. 
The first branch point separated 4 tissue-resident macrophage clusters (healthy lung FABP4+ and FAB-
P4loFCN–SPP1+, and synovial lining TREM2hi and TREM2lo) from the other BALF and STM clusters that 
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Figure 1. COVID-19 BALF FCN1+ and FCN1+SPP1+ macrophage clusters are transcriptionally related to rheumatoid arthritis synovial CD48hiS100A12+ and 
CD48+SPP1+ macrophage clusters. (A and B) UMAP of an equal number of synovial tissue and BALF macrophages (32,000 from each data set), colored 
according to their ST and BALF cluster identification. (C) Dendrogram of hierarchical clustering analysis of integrated pseudobulk gene expression (average 
expression in each cluster) of ST and BALF clusters. (D) Venn diagram illustrating the numbers of unique and shared marker genes of ST CD48hiS100A12+ 
and BALF FCN1+ clusters. P < 0.05 after Bonferroni correction for multiple comparisons. (E) Heatmap illustrating scaled, pseudo-bulk gene expression of 
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were likely of  monocytic origin (19, 24, 25). The split-points and distances in the second branch of  hierar-
chical clustering indicate that the proinflammatory clusters (i.e., FCN1+ and FCN1+SPP1+) that dominate 
in severe COVID-19 share transcriptomic profiles with proinflammatory clusters (i.e., CD48hiS100A12+ 
and CD48+SPP1+, respectively) in active RA. Pearson correlation analysis between BALF FCN1+ and ST 
CD48hiS100A12+, and between BALF FCN1+SPP1+ and ST CD48+SPP1+, confirmed resemblance (r = 
0.56, P = 2.2 × 10–16 and r = 0.65, P = 2.2 × 10–16) of  respective BALF/ST pairs. Independent differential 
gene expression analysis identified striking similarities in the pathogenic pathways of  COVID-19 pneumo-
nitis FCN1+ and active RA synovitis CD48hiS100A12+ clusters. They share 238 top marker genes (Figure 
1D) that include upregulation of  inflammatory and prothrombotic pathways. These consisted of  IFN path-
way (e.g., IFITM2, IFITM3, and ISG15), inflammation-triggering alarmins (S100A8/9/12A), B cell activa-
tion factors (e.g., BAFF-TNFSF15B), promotors of  IL-1β and TNF production (e.g., CARD16 and LITAF), 
prothrombotic factors (e.g., FGL2), and integrins mediating cell migration and adhesion (e.g., ITGB2 and 
ITGX). They also share receptor expression profiles — e.g., TNFR2 (TNFRSF1B), G-CSFR (CSF3R), and 
the complement receptor (C5aR; ref. 38) — that may render them increasingly susceptible to proinflam-
matory mediators to further escalate inflammation (Figure 1E). The hierarchical analysis and comparison 
of  cluster markers also indicate a shared transcriptional profile of  COVID-19 FCN1+SPP1+ and synovitis 
CD48+SPP1+ clusters consisting of  86 common marker genes including SPP1, which have broad proinflam-
matory and fibrotic functions (Figure 1, F and G) (39). These transcriptomic profiles suggest that BALF 
FCN+ and FCN+SPP1+ macrophage clusters predominant in severe COVID-19 shared pathogenic molec-
ular pathways, including the expression of  their signature mediators S100A12 and SPP1 (Figure 1H) with 
ST CD48hiS100A12+ and CD48+SPP1+ clusters predominant in active RA. Analysis of  SPP1 and S100A12 
expression in other cell types present in lung tissue (Figure 1I and Supplemental Figure 2) demonstrated that 
BALF macrophage populations are the main cells expressing SPP1 and S100A12 in severe COVID-19, and 
due to their high numbers in BALF of  severe COVID-19(Supplemental Figure 1), FCN+ and FCN+SPP1+ 
macrophage clusters are likely the main contributors to the S100A12 and SPP1 pool in the COVID lung.
Healthy lung alveolar FABP4+ macrophages share a homeostatic regulatory transcriptomic profile, including the TAM 
pathway, with ST lining layer TREM2hi macrophages. The innate immune pathways that restrain inflammation in 
acute COVID-19 are yet to be characterized. Recently uncovered innate mechanisms reinstating ST homeo-
stasis in RA (19) might shed new light on potential mechanisms of  resolution for COVID-19. The ST of  RA 
patients in sustained disease remission is dominated by macrophage clusters with protective and inflamma-
tion-resolving properties (19). Of these resolving clusters, ST TREM2hi clustered tightly with the FABP4+ AM 
cluster in unsupervised hierarchical analysis (Figure 1C). Pearson correlation of  986 TREM2+ and FABP4+ 
unique and common cluster markers (r = 0.83 P = 2.2 × 10–16) confirmed the similarities. Differential expres-
sion analysis of  their profiles identified that BALF FABP4+ and ST TREM2hi clusters share 170 markers indi-
cating analogous homeostatic functions (Figure 2, A and B). These include the complement pathways (e.g., 
C1q) that facilitates uptake of  apoptotic bodies, high expression of  genes of  retinoic acid production (e.g., 
ALDH1A1 and RBP4) that drives Treg differentiation (40), and the B7-related coinhibitory molecule VSIG4 
that inhibits T effector cells (41); this suggests a primary role of  this cluster in governing lung immunity (Fig-
ure 2B). While the functional contribution of  FABP4+ macrophages to the resolution of  SARS-CoV-2 infec-
tion is yet to be established, we have shown previously that their counterpart TREM2+ STM clusters produced 
inflammation-resolving lipid mediators and induced a repair phenotype in tissue stromal cells that maintain 
disease remission. These homeostatic responses were driven by MerTK, a member of  the immunosuppressive 
tyrosine kinase receptor TAM family (TYRO, AXL, and MerTK; ref. 19). TAM receptors and their ligands 
GAS6 or the PROS1 gene product Protein S (PROS1) form a homeostatic brake on inflammation and auto-
immunity (42–44). In addition, Protein S is an essential inhibitor of  blood coagulation preventing thrombosis 
(45). Lung-resident FABP4 macrophages uniquely express AXL rather than MerTK. Their AXL is constitu-
tively ligated to GAS6 (46, 47) and is key in preventing exacerbated inflammation — e.g., during influenza 
shared upregulated marker genes (highlighted in D) by BALF and ST clusters. (F) Venn diagram illustrating numbers of unique and shared marker genes 
of ST CD48+SPP1+ and BALF FCN1+SPP1+ clusters generated as in E. (G) Heatmap illustrating scaled, pseudobulk gene expression of shared upregulated 
marker genes (highlighted in F) by ST and BALF clusters. (H) Split UMAP plots comparing S100A12 and SPP1 expression in BALF and ST macrophage 
clusters across different conditions. Intensity of purple indicates expression level. HC, healthy control. (I) Dot plots illustrating normalized (mean ± SEM) 
expression values of S100A12 and SPP1 per cell across all immune and epithelial cell clusters in severe COVID-19 BALF (n = 6). Framed populations showed 
the highest expression of these markers.
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Figure 2. COVID-19 BALF FABP4+ and RA synovial TREM2+ macrophages share transcriptom-
ic profiles and regulatory TAM receptor pathways. (A) Venn diagram illustrating numbers 
of unique and shared marker genes of ST TREM2hi and BALF FABP4+ macrophage clusters as 
described in Figure 1. Marker genes were identified prior to integration of data sets (19, 24) 
and were calculated using MAST, setting a minimum percentage of cells in clusters expressing 
each marker to 40%. Genes considered differentially expressed at P < 0.05 after Bonferroni 
correction. (B) Heatmap illustrating scaled, pseudobulk expression of shared upregulated 
marker genes from ST and BALF clusters indicated in A. (C) Split UMAP plots comparing 
BALF macrophage clusters in health, and in mild and severe COVID-19, illustrating changes in 
expression of the TAM receptors AXL and MerTK, with their respective preferred ligands GAS6 
and PROS1. Intensity of purple indicates expression level. (D) Heatmap illustrating scaled, 
pseudobulk expression of TAM receptors and associated ligands by each BALF cluster, across 
patient groups. TAM receptors and their ligands were significantly differentially expressed in 
severe COVID-19 versus healthy tissues (P ≤ 0.005), with Bonferroni correction for multiple 
comparison, as confirmed by MAST.
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virus infection (46, 47). Analysis of  the GSE145926 data set (24) identified profoundly altered macrophage 
expression of  TAM receptors and their ligands in the lung (Figure 2, C and D) that might explain the inade-
quate regulation of  the tissue hyperinflammatory and thrombotic responses in severe COVID-19. The TAM 
receptors and ligand pathway was mostly expressed by lung myeloid cells, with a contribution from ciliated 
epithelium to the lung Protein S pool (Supplemental Figures 2 and 3). AM from healthy lungs showed high 
expression levels of  AXL and PROS1, and these were markedly reduced in patients with severe COVID-19 
(Figure 2, C and D). GAS6 and MerTK were not expressed by resident AMs; instead, they were increasingly 
expressed by infiltrating FCN+ and FCN+SPP1+ macrophage clusters, suggesting an inflammation-triggered 
attempt to counterbalance pathogenic responses. However, the reduced PROS1, which is the preferred acti-
vating ligand for MerTK (44, 48), and the fewer homeostatic resident AMs in severe COVID-19 might enable 
unrestricted proinflammatory cytokine production by locally differentiated MerTK-expressing FCN+ and 
FCN+SPP1+ macrophages.
High plasma SPP1 is associated with a severe disease trajectory of  COVID-19. To validate the computational 
scRNAseq findings of  shared pathogenic macrophage clusters in COVID-19 and RA, we quantified plas-
ma concentrations of  their key shared functional mediators SPP1 (osteopontin) and S100A12 (calgranulin 
C) in a cross-sectional comparison of  additional patient groups. These consisted of  (a) hospitalized acute 
COVID-19 patients (n = 92), (b) COVID-19 patients in their post–COVID-19 phase (convalescence) at out-
patient clinics (n = 41), (c) hospitalized patients with non–SARS-CoV-2 community–acquired severe acute 
pneumonia (n = 29), and (d) healthy donors (n = 10; Figure 3A). Demographic and clinical information, 
and laboratory biomarkers are presented in Supplemental Table 1. Blood samples for groups (a) and (c) were 
taken on hospital admission or shortly afterward and before antiinflammatory treatment (see Methods).
Patients with acute COVID-19 had significantly higher plasma levels of  proinflammatory SPP1 and 
S100A12 than healthy donors and patients at the post–COVID-19 stage (Supplemental Figure 4A). Based 
on clinical criteria (see Methods) and before antiviral/antiinflammatory treatment administration, the 
acute COVID-19 patients were categorized into those who subsequently developed either mild/moderate 
or severe disease. We found that the S100A12 plasma levels were higher in COVID-19 patients categorized 
as severe compared with mild/moderate, and compared with those in convalescence, and with healthy 
donors, but comparable with the levels in patients with community acquired pneumonia (Figure 3B). Inter-
estingly, levels of  SPP1 were uniquely higher in those with severe COVID-19 compared with any other 
groups, including severe pneumonia induced by other pathogens (Figure 3B).
We next investigated the relationship between plasma levels of  SPP1 and S100A12, with systemic 
inflammation measured by blood cytometry and biochemistry, and lung function measured by PaO2/FiO2 
tested around the time of  blood sampling and before administration of  antiinflammatory treatment (Sup-
plemental Table 1). Plasma concentrations of  SPP1 and S100A12 correlated negatively with PaO2/FiO2 
and positively with inflammatory biomarkers — e.g., IL-6, CRP, and LDH (Figure 3C and Supplemental 
Table 1). Moreover, SPP1 and S100A12 each strongly correlated with the neutrophil/lymphocyte ratio, 
which itself  is a prognostic biomarker for COVID-19 severity (Figure 3C) (49). Stratification of  patients 
according to levels of  PaO2/FiO2 reflecting those with or without severe respiratory distress (PaO2/FiO2 
≤ 200 and PaO2/FiO2 > 200, respectively) clearly showed that the former had significantly higher levels of  
SPP1 and S100A12 (Figure 3D). A refinement of  this observation suggested that COVID-19 patients with 
plasma levels of  SPP1 ≥ 108 ng/mL and S100A12 ≥ 59 ng/mL (cut-off  values based on their medians in 
all COVID-19 patients) were predictive of  those more likely to have severe respiratory distress (PaO2/FiO2 
≤ 200) compared with those with lower SPP1 and S100A12 levels (Figure 3E and Supplemental Figure 4B). 
Of prognostic importance for COVID-19 patients, higher levels of  SPP1 and S100A12 at the time of  hospital 
admission and before antiinflammatory treatment were predictive of  urgency for subsequent Intensive Care 
Unit (ICU) transfer (Figure 3, F and G). The time to ICU transfer was significantly more rapid for patients 
with plasma SPP1 ≥ 108 ng/mL and S100A12 ≥ 59 ng/mL (Figure 3H). These data suggest that a plasma 
biomarker signature associated with pathogenic macrophage clusters in the lung and shared with RA syno-
vitis (i.e., SPP1 and S100A12) might be useful for predicting the trajectory of  disease severity and indicative 
of  mechanism of  pathogenesis of  severe COVID-19. Analysis of  the SPP1 (CD44/integrins) and S100A12 
(TLR4/CD36) receptor distribution in the lungs of  COVID-19 patients demonstrated that many cell types 
expressed receptors for SPP1, including macrophages, neutrophils, T cells, and epithelial cells, whereas pre-
dominantly macrophages expressed receptors for S100A12 (Supplemental Figure 5). This suggested that the 
lungs acted as a receptive environment for the actions of  proinflammatory SPP1 and S100A12.
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We next investigated the plasma concentrations of COVID-19/RA shared regulatory TAM receptor path-
way ligands GAS6 and PROS1 in the patient groups described above. They showed a distinct plasma signature 
compared with proinflammatory SPP1 and S100A12. At the time of acute pneumonia, plasma levels of GAS6, 
the preferable ligand for the AXL receptor, did not differ between acute severe COVID-19 and healthy donors. 
However, GAS6 levels were lower in patients with milder acute COVID-19 and in post–COVID-19 subjects in 
whom acute inflammation had resolved, compared with healthy donors and patients with severe COVID-19 
(Figure 3B). Consistent with lower levels of GAS6 in patients with mild/moderate disease, GAS6 levels in 
COVID-19 patients correlated negatively with PaO2/FiO2 ratio (Figure 3C). COVID-19 patients with PaO2/
FiO2 > 200 had lower plasma GAS6 levels than those with PaO2/FiO2 ≤ 200 (Figure 3D), and optimum cut-off  
plasma levels of GAS6 < 24 ng/mL detected those more likely to maintain good lung function (PaO2/FiO2 > 
200) (Figure 3E). Prognostically, low levels of GAS6 at the time of hospital admission and/or before antiin-
flammatory treatment were predictive of low risk for ICU transfer (Figure 3F); for example, 6.5% of COVID-19 
patients with GAS6 < 24 ng/mL required transfer to ICU compared with 44.4% of those with GAS6 ≥ 24 ng/
mL (Figure 3, G and H). These data suggest that lower GAS6 levels were predictive of better disease outcomes. 
GAS6 can be produced by many immune cells (45, 50), including lung-infiltrating inflammatory FCN1+ and 
FCN+SPP1+ macrophages and DCs (Figure 2C and Supplemental Figure 2). Thus, low levels of plasma GAS6 
in patients with milder disease may reflect a lower degree of lung infiltration by inflammatory macrophages.
Plasma level of PROS1, a marker of healthy lung FABP4+ macrophages and the preferable ligand for 
MerTK, did not differ between any of the COVID-19 patient categories or healthy donors (Figure 3B). Howev-
er, the levels of PROS1 in COVID-19 patients with mild/moderate disease showed a wider spread of the val-
ues as illustrated by interquartile range compared with other groups, suggesting potential association between 
PROS1 and individual composites of the classification criteria. In contrast to SPP1, A100A12, and GAS6, 
PROS1 levels correlated positively with PaO2/FiO2 and negatively with IL-6 (Figure 3C). COVID-19 patients 
with PaO2/FiO2 > 200 had higher plasma levels of PROS1 than those with PaO2/FiO2 ≤ 200 (Figure 3D). 
An optimum plasma PROS1 cut-off  value was calculated at 15 μg/mL, above which 34.1% of COVID-19 
patients had severe respiratory distress as compared with 59% of those with PROS1 < 15 μg/mL (Figure 3E). 
This observation is consistent with the single-cell transcriptomic data (Figure 2C) showing that the expression 
of inflammation resolving, antithrombotic PROS1 and antithrombotic PROS1 in resident alveolar FABP4+ 
macrophages decreases with increasing disease severity.
Next, we investigated whether concomitant pharmacological drug treatment, demographic factors 
(age and sex), and COVID-19 comorbidities (6) contributed to the plasma levels of  SPP1, S100A12, 
GAS6, and PROS1. None of  the pharmacological treatments affected the plasma levels of  SPP1, 
S100A12, GAS6, and PROS1 in moderate and severe COVID-19 pneumonia (Supplemental Figure 6). 
S100A12 and PROS1 were unrelated to age in COVID-19 and in SARS-CoV-2– pneumonia (Supple-
mental Figure 4, C–E). SPP1 was unaffected by age in SARS-CoV-2– pneumonia but was higher in 
COVID-19 patients > 70 years old (Supplemental Figure 4, C–E), suggesting that SPP1 levels are related 
more to severity of  pneumonia than age (Figure 3). GAS6 was higher in COVID-19 and non–SARS-
CoV-2 pneumonia patients > 70 years old and higher in COVID-19 patients with arterial hypertension, 
diabetes mellitus, and ischemic cardiopathy (Supplemental Figure 7); thus, age and comorbidities may 
confound interpretation of  increased GAS6 in COVID-19.
Figure 3. High levels of SPP1 and S100A12 are associated with a severe COVID-19 disease trajectory. (A) Patients and healthy donors, shown as the 
following: n = 121 patients with acute pneumonia (n = 29 community acquired SARS-CoV-2– pneumonia, n = 29 mild/moderate COVID-19, n = 63 severe 
COVID-19), convalescent COVID-19 (n = 41), and healthy controls (n = 10). Representative images of lung CT scans. (B) Plasma levels of SPP1, S100A12, 
GAS6, and PROS1 in groups as in A. (C) Spearman’s rank correlations between SPP1, S100A12, GAS6, and PROS1 plasma levels in patients with acute 
COVID-19 pneumonia (n = 92) with demographic and clinical parameters. Each box displays the r value, and an asterisk indicates statistical significance 
of P < 0.05. (D) Plasma levels of SPP1, S100A12, GAS6, and PROS1 in patients with acute COVID-19 pneumonia (n = 92) stratified based on lung functions 
measured by PaO2/FiO2 at the time of hospital admission. Severe respiratory failure was defined by PaO2/FiO2 ≤ 200. (E) Percentage of acute COVID-19 
pneumonia patients (n = 92) with PaO2/FiO2 ≤ 200 based on high plasma levels of SPP1 (≥108 ng/mL), S100A12 (≥59 ng/mL), GAS6 (≥24 ng/mL), and 
PROS1 (≥15 μg/mL). (F) COVID-19 patient plasma levels of SPP1, S100A12, GAS6, and PROS1 at the time of hospital admission (n = 92) stratified based 
on a patient’s subsequent need to be transferred to ICU. (G) Percentage  of patients with acute COVID-19 pneumonia (n = 92) transferred to ICU during 
the hospitalization based on having high levels of SPP1 (≥108 ng/mL), S100A12 (≥59 ng/mL), GAS6 (≥24 ng/mL), and PROS1 (≥15 μg/mL) at the time of 
hospital admission. (B, D, and F) Data are presented as violin plots with median and interquartile range. Asterisk indicates 1-way ANOVA (Kruskal-Wallis 
test) with Dunn’s correction for multiple comparisons if more than 2 groups were compared (B), or 2-sided Mann-Whitney U was used when 2 groups were 
compared (B and D–G). (H) Kaplan-Meier analysis of the rate of transfer of COVID-19 patients to ICU based on their cut-off values for SPP1, S100A12, GAS6, 
and PROS1 at the time of hospital admission.
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Increased SPP1 levels persist after COVID-19. We investigated the persistence of increased plasma SPP1, 
S100A12, GAS6, and PROS1 into the SARS-CoV-2– post–COVID-19 phase, often characterized by complex 
pathologies (26). We compared plasma concentrations in 41 post–COVID-19 patients attending outpatient clinic 
at (mean ± SEM) 68.60 ± 4.36 days after discharge (Figure 4A), 26 of whom had plasma samples that were 
available from the peak of acute COVID-19. Longitudinal comparison showed that plasma levels of SPP1, 
S100A12, and GAS6 were significantly lower in convalescence compared with peak disease, but PROS1 was 
unchanged (Figure 4B). However, although reduced, the levels of SPP1 and S100A12 remained significantly 
higher than in healthy control donors, irrespective of whether the prior disease trajectory of COVID-19 was 
mild/moderate or severe (Figure 4C). This was in contrast to the levels of sensitive markers of inflammation, 
Figure 4. Increased SPP1 and S100A12 levels persist in post–COVID-19 phase. (A) Representative images of lung CT scans (transversal and sagittal 
view) of a COVID-19 patient taken during acute pneumonia and during convalescence (68.60 ± 4.36 days after hospital discharge). (B) Plasma levels of 
SPP1, S100A12, GAS6, and PROS1 in paired plasma samples from COVID-19 patients at the time of acute pneumonia and at the convalescent phase (n 
= 26). (C) Plasma levels of SPP1, S100A12, GAS6, and PROS1 in convalescent COVID-19 patients (n = 41) stratified based on the severity of prior acute 
pneumonia and compared with the levels of healthy donors (n = 10). (D) Plasma levels of IL-6 in acute pneumonias and post–COVID-19. (E) SPP1, 
S100A12, GAS6, and PROS1 in convalescent COVID-19 patients (n = 41) stratified based on suffering (n = 36) or not (n = 5) at least 1 of the symptoms 
(fatigue, musculoskeletal, or respiratory symptoms). (B) Data are presented as before-and-after plot. Wilcoxon test on paired samples was used, 
and exact P values are provided on the graphs. (C–E) Data are presented as violin plots with median and interquartile range. Asterisks indicate 1-way 
ANOVA with correction for multiple comparisons if more than 2 groups were compared, or 2-sided Mann-Whitney U test was used when 2 groups 
were compared (C–E). Exact P values are provided on the graphs.
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including IL-6 and LDH, which normalized in post–COVID-19 to levels of those in healthy donors, consistent 
with resolved acute inflammation (Figure 4D and Supplemental Table 1). GAS6, lower than normal control lev-
els in mild/moderate COVID-19 on hospital admission (Figure 3B), remained low after COVID-19 (Figure 4C).
Most (36 of  41) convalescent patients reported persistence of  at least 1 post–COVID-19 symptom 
(fatigue, musculoskeletal, or respiratory). Increased levels of  SPP1 and S100A12 persisted in all patients, 
although extremely high concentrations SPP1 were restricted to symptomatic patients (Figure 4E). Strat-
ification of  patients by symptoms showed that SPP1 and S100A12 levels remained increased and GAS6 
decreased in convalescent COVID-19 patients, irrespective of  symptom category (Supplemental Figure 8).
Together, these data suggest that the SPP1 and S100A12 myeloid cell inflammatory signature persists after 
resolution of SARS-CoV-2 infection and may contribute to the pathogenesis of long–COVID-19 syndrome (26).
SPP1 protein is expressed by COVID-19 BALF macrophages, drives proinflammatory activation of  classical 
monocytes, and the differentiation of  neutrophils toward a proinflammatory CD274+ (PD-L1+) phenotype. High 
plasma SPP1 selective for severe COVID-19 (Figure 3B) suggested a role for SPP1 in pathogenesis. 
Figure 5. SPP1 protein is expressed in COVID-19 lung by macrophages but not healthy alveolar macrophages. 
(A) Representative immunofluorescence staining of normal lung (n = 3) showing SPP1– alveolar macrophage 
(CD68+). (B) Representative immunofluorescence staining of COVID-19 lung (n = 2) showing SPP1+ macrophages 
(CD68+SPP1+) in alveoli. Solid white arrows indicate macrophages double-positive for SPP1 and CD68; hollow arrows 
indicate CD68+ and SPP1– macrophages.
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Figure 6. SPP1 stimulation drives proinflammatory CD14+ monocyte and CD274+ (PD-L1+) neutrophil phenotypes. Whole blood cells from healthy donors 
(n = 3) were stimulated with SPP1 (50 or 200 ng/mL) or were unstimulated, for 16 hours. (A) UMAP of 13,580 integrated control and SPP1-stimulated blood 
cells colored by cluster identity. (B) Stacked bar plot illustrating cluster proportion of total whole blood cells per condition/dose of SPP1. * P < 0.05, 1-way 
ANOVA with correction for multiple comparisons. (-), unstimulated control. (C) UMAPs illustrating change in expression of MME (CD10) and CD274 (PD-L1) 
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SPP1 and CD68 staining of  postmortem lung tissue confirmed abundant clusters of  SPP1+ macro-
phages in alveoli of  COVID-19 patients (n = 2), while it was rare in normal lung (n = 3; Figure 5, A and 
B and Supplemental Table 2) and sparse in alveoli of  bacterial (n = 3) and H1N1 (n = 3) pneumonia 
(Supplemental Figure 9, A and B). To investigate the biological effects of  SPP1, we stimulated healthy 
whole blood cells with SPP1 at concentrations equivalent to those in severe and post–COVID-19 (200 
and 50 ng/mL, respectively) (Figure 3B). SPP1 receptors (e.g., CD44/integrins) are expressed by many 
immune cell types in lung and blood (Supplemental Figure 5 and Supplemental Figure 10); therefore, 
to capture the effects of  SPP1 on all cell types, we used scRNAseq of  the whole blood culture (n = 3 
healthy donors) using the immune gene panel (399 genes) with the BD_Rhapsody system after 16-hour 
stimulation with SPP1. We sequenced 13,580 cells and identified 14 distinct immune clusters (Figure 
6, A and B), including neutrophil, eosinophil, monocyte, DC, NK cell, and lymphocyte cell clusters. 
The relative proportions of  cell clusters revealed that SPP1 stimulation at 200 ng/mL, equivalent to 
plasma concentration of  severe COVID-19, was associated with a significantly increased neutrophil 
proportion (Figure 6, B and C) with a shift from the normally dominant CD10+ (MME+) neutrophil 
phenotype to a CD274+ (PD-L1+) neutrophil phenotype. The top 20 marker genes of  the CD10+ and 
SPP1-differentiated CD274+ (PD-L1+) neutrophil clusters (Figure 6D and Supplemental Data) revealed 
that the CD274+ (PD-L1+) neutrophils represent an aberrantly activated phenotype characterized by 
high expression of  PD-L1 (CD274), which mediates suppression of  adaptive immunity, high levels of  
proinflammatory cytokines/chemokines (e.g., IL1B, TNF, CCL3, and CCL4), c-type lectins (CLEC4E/D) 
that facilitate neutrophils migration, and the SPP1 receptor CD44. Similar aberrant neutrophil acti-
vation is a key pathogenic characteristic of  severe COVID-19 (51, 52). To investigate if  the in vitro 
SPP1-driven neutrophil cluster transcriptionally replicated any of  the neutrophil phenotypes observed 
in severe COVID-19, we performed unsupervised mapping of  the SPP1-driven neutrophil gene module 
(37 genes; Supplemental Data) into a whole-blood scRNAseq transcriptomic signature of  healthy, mild, 
and severe COVID-19 (22). We identified that enrichment of  transcriptional signature of  SPP1-driven 
CD274+ (PD-L1+) neutrophils was significantly higher in Neutrophil_2 phenotype than any other cell 
population (Figure 6, E and F) in COVID-19 patients and that this phenotype was uniquely increased 
in severe disease, suggesting that SPP1 might be responsible for the pathogenic activation of  neutrophils 
in severe COVID-19. This link between SPP1 and neutrophils is supported by the correlation between 
plasma SPP1 and the blood neutrophils/lymphocytes ratio in our COVID-19 cohort (Figure 3C).
Our analysis also revealed that SPP1 induced the activation of  CD14+ classical monocytes. At 200 ng/
mL, SPP1 strongly increased the expression of  alarmins (S100A12, S100A9), IL-1β, and chemokines (CXCL8, 
CCL2-4) with a commensurate reduction of  MHCII and antiinflammatory ENTPD1 (encoding CD39; Figure 
6G), which resembles the proinflammatory changes in the blood CD14+ monocyte subset in severe COVID-19 
(22, 23). SPP1 at post–COVID-19 convalescent plasma concentration (50 ng/mL) did not affect neutrophil 
activation. However, it increased expression levels of  alarmins S100A12 and S100A9, and it decreased the 
expression of  MHCII and ENTPD1 of CD14+ monocytes (Figure 6G), suggesting that persistent levels of  
SPP1 may contribute to long–COVID-19 pathologies by skewing monocytes toward a proinflammatory 
phenotype. The effect of  SPP1 on other cell types was minimal (Supplemental Data). In summary, SPP1 
produced by proinflammatory lung-infiltrating macrophages might be an upstream activator of  the aberrant 
innate response in COVID-19 by driving proinflammatory activity of  CD14+ monocytes and differentiation 
of  CD274+ (PD-L1+) neutrophils that suppress adaptive immunity and support inflammation.
Discussion
Our comparative single-cell transcriptomic analysis integrating myeloid cell clusters from COVID-19 pneu-
monitis and RA synovitis suggested that COVID-19 and RA pathogenesis and resolution might be driven by 
similar myeloid cell clusters and their signature functional pathways (Supplemental Figure 11). The shared 
by neutrophil clusters following SPP1 stimulation. (D) Heatmap showing expression of the top 20 marker genes of each neutrophil phenotype, illustrated 
as average expression of each gene per sample per condition. Adjusted P < 0.05, MAST with Bonferroni correction. (E) Average of SPP1-driven CD274+ 
neutrophil gene module score by neutrophil clusters of COVID-19 whole blood cell data set (22). (F) UMAP expression of the SPP1-driven CD274+ neutrophil 
gene module in COVID-19 whole blood data set. (G) Heatmap showing expression of genes significantly differentially expressed in CD14+ monocytes com-
paring SPP1 (200 ng/mL) stimulation with unstimulated control, illustrated as average expression of gene per condition. Adjusted P < 0.05, MAST with 
Bonferroni correction. Red and orange arrows in D and G represent genes regulated by 200 ng/mL only, or by 200 and 50 ng/mL SPP1, respectively.
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key pathogenic macrophages were SPP1+ and S100A12+ clusters, and their signature SPP1 and S100A12 
mediators were confirmed in COVID-19 cross-sectional and longitudinal patient plasma samples. COVID-19 
patients with severe respiratory distress were characterized by an aberrant raised SPP1 and S100A12 cyto-
kine signature that could predict the urgency for ICU transfer and persisted into the post–COVID-19 phase 
after hospital discharge. An abundance of  SPP1+ macrophages in the alveolar spaces and high SPP1 plasma 
levels were unique to severe COVID-19 pneumonia as compared with pneumonias induced by other patho-
gens. Investigation into SPP1 mechanisms of  action revealed that it drives proinflammatory activation of  
CD14+ monocytes and development of  PD-L1+ pathogenic neutrophils, both hallmarks of  severe COVID-19 
(1–14). Thus, COVID-19 pneumonitis appears driven by similar pathogenic myeloid cell pathways as those 
in RA, and their mediators such as SPP1 may be an upstream activator of  the aberrant innate response in 
severe COVID-19 and predictive of  disease trajectory including post–COVID-19 monitoring.
In contrast, COVID-19 patients with milder respiratory distress were characterized by increased plas-
ma levels of  the inflammation-resolving, antithrombotic cytokine PROS1, which characterized the resident 
AM FABP4+ cluster. This cluster shared transcriptomic similarities with the inflammation-resolving STM 
TREM2+ cluster, suggesting a potential role in controlling lung inflammation.
The BALF FCN1+ and FCN1+SPP1+ macrophage clusters from severe COVID-19 patients shared tran-
scriptomic profiles with STM CD48hiS100A12+ and CD48+SPP1+ clusters from active RA, respectively. The 
functional biology of  the STM counterparts (i.e., CD48hiS100A12+ and CD48+SPP1+) showed that they were 
the main producers of  pathogenic TNF, IL-6, IL-1β, and chemokines in the synovium of RA, and this resem-
bles the lung hypercytokine environment characterizing severe COVID-19 respiratory distress syndrome (53, 
54), suggesting that SPP1+ and S100A12+ BALF macrophage clusters might be the key source of  these medi-
ators in the COVID-19 lung. These shared macrophage clusters of  RA/COVID-19 are also characterized 
by their cluster-unique mediators, SPP1 (CD48+SPP1+ cluster) and S100A12 (CD48hiS100A12+cluster; ref. 
19). These mediators were upregulated in severe compared with mild/moderate COVID-19, and their high 
plasma concentrations correlated with respiratory insufficiency and was predictive for urgency of  ICU trans-
fer. The increased number of  SPP1+ macrophages and upregulation of  SPP1 plasma levels were selective for 
severe COVID-19. Many biological functions for SPP1, mostly in tissue remodeling, have been described (39, 
55). However, its contribution to COVID-19 pathologies is unclear. We revealed here that SPP1 at the level 
detected in patients with severe COVID-19 is a potent driver of  pathogenic PD-L1+ neutrophils that are char-
acteristic of  severe COVID-19 (22). Thus, SPP1 might be an upstream regulator of  neutrophil-mediated tissue 
damage and immune-thrombosis that are key pathogenic features of  severe COVID-19 (51, 52). In addition, 
SPP1 induced strong proinflammatory activation of  CD14+ monocytes, including the expression of  S100A 
alarmins, suggesting that it may contribute to the development of  S100A12+ macrophage clusters in the lung.
There is an increasing recognition of  a syndrome of  persistent debilitating symptoms after the 
COVID-19 patients become negative for SARS-CoV-2 (post–COVID-19). The symptom patterns are com-
plex, but dyspnoea and fatigue are prominent (26). The pathogenic mechanisms of  this syndrome are 
unknown. Emerging transcriptomic evidence shows that changes in blood myeloid cells elicited during 
acute infection can normalize within 14 days of  becoming negative for SARS2-CoV-2 (56). However, 
some changes can persist for at least 12 weeks, including high levels of  surface molecules that regulate 
monocyte migration into tissue — e.g., CXCR6 and VLA-4 (57). We found that — in contrast, for example, 
to IL-6 — plasma SPP1 and S100A12 remained significantly higher than normal for at least 10 weeks after 
infection clearance in the post–COVID-19 convalescent phase. Our study revealed that SPP1, at the con-
centration detected in the post–COVID-19 stage, induced some of  the features of  proinflammatory CD14+ 
monocytes — for example, an increase in alarmins (S100A12 and S100A9) and a decrease in MHCII mol-
ecules. This suggests that a sustained raised level of  SPP1 may contribute to post–COVID-19 pathologies 
and may influence future responses against pathogens by skewing monocytes toward proinflammatory 
phenotype. At this stage of  understanding, it remains unclear whether the plasma SPP1 and S100A12 
exclusively originate from the pathogenic BALF clusters persisting in the lung of  these patients. However, 
regardless of  SPP1 and S100A12 source, their wide range of  proinflammatory and fibrotic functions may 
be responsible for the respiratory and musculoskeletal symptoms that persist in convalescence.
One of  the aims of  this study was to apply our recent discovery of  inflammation-resolving macro-
phage pathways in RA to investigate potentially similar inflammation-resolving pathways for COVID-19. 
We found that tissue-resident lung alveolar FABP4+ macrophages and homeostatic synovial lining lay-
er TREM2+ macrophages share transcriptomic profiles. This may reflect their homeostatic functions 
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in their respective tissues. In the synovium, the TREM2+ macrophages form a lining-layer producing 
and recycling lubricant synovial fluid, which facilitates joint movement (58). While in lung alveoli, the 
FABP4+ macrophages contribute to alveolar integrity, the recycling of  surfactants to maintain patency, 
and the facilitation of  gas exchange (33). One of  the pathways they shared was inflammation-resolv-
ing TAM (TYRO, AXL, MerTK) receptor pathways. TAM pathways are widely expressed by resident 
macrophages in many tissues (59, 60), and their deregulation has proinflammatory/autoimmune conse-
quences in preclinical animal models (61, 62) and in patients with RA (19). The scRNAseq data show 
that, in healthy human BALF, the FABP4+ macrophages express the TAM receptor AXL and the ligand 
for the TAM receptor MerTK (PROS1) and that these were profoundly repressed in severe COVID-19. 
Consistent with scRNAseq data, plasma Protein S levels were higher in COVID-19 patients who main-
tained lung functions (i.e., sustained PaO2/FiO2 > 200), suggesting a potential role in counterbalancing 
the severity of  inflammation of  SARS-CoV-2 infection.
Limitations of  the study included the younger age and fewer numbers of  subjects within the healthy 
control group used as a comparator of  some of  the COVID-19 analysis. These limitations were mitigated 
by findings that SPP1, S100A12, and PROS1 were unaffected by age. In addition, the control group for 
the key mediator SPP1 in severe COVID-19 was the non–SARS-CoV-2 pneumonia group that matched 
COVID-19 for age, and it showed lower levels of  SPP1 compared with COVID-19, supporting the link 
between SPP1 and COVID-19 pathogenesis.
In summary, this study suggests that the pathogenesis of  acute severe COVID-19 pneumonitis and RA 
synovitis might be driven by similar pathogenic myeloid cell clusters/pathways, producing SPP1 that persists 
into post-COVID-19 syndrome. Further functional studies on identification of  common tissue factors driving 
the differentiation of  these pathogenetic macrophage clusters and better understanding the functional interac-
tion between them and the lung environment could clarify mechanisms of  pneumonitis and provide evidence 
for potential repurposing of  current antiinflammatory/antifibrotic treatments for COVID-19 (63, 64). Promis-
ing data from current COVID-19 clinical trials of  drugs already used for the treatment of  RA (e.g., dexameth-
asone, tocilizumab, and baricitinib; refs. 35, 65–69) further support the concept of  common pathogenic and 
resolution mechanisms that could be capitalized upon for COVID-19 therapeutic exploitation.
Methods
Data acquisition and analysis
Comparison and integration of  BALF and ST myeloid cell scRNAseq data. BALF data were acquired as Cell-
Ranger output (GEO, GSE145926) and ST data were acquired from EMBL-EBI:E-MTAB-8322. COVID-19 
blood and PBMC data (22) were from https://beta.fastgenomics.org/p/schulte-schrepping_covid19.
Quality checks, filtering, clustering of 10X Genomics data sets
Seurat (3.1.2) in R created an object (CreateSeuratObject). Cell-filtering involved removal of  cells with < 500 
expressed genes (subset, subset = nFeatures_RNA > 500), with set-thresholds for gene-expression level, 
including mitochondrial genes (percent.mt) to exclude doublets and dying cells. Data normalized using 
Seurat’s NormalizeData function. Myeloid cells were filtered for expression of  CD14, MARCO, and 
LYZ with the subset function. The top 2000 variable genes were identified using the FindVariableFeatures 
function. Sample integration of  each data set followed the Seurat vignette, integrating all genes common 
between samples of  each condition, using FindIntegrationAnchors and IntegrateData functions (features.
to.integrate to normalize all common genes).
Individual clustering and dimensional reduction. UMAP based on PCA cell embeddings were generated 
by Seurat for each data set using RNA assay. To visualize ST data, the first 12 principal components were 
used (RunUMAP). These principal components determined the k-nearest neighbors for each cell during 
shared nearest neighbor (SNN) graph construction before clustering at a resolution of  0.5 (FindNeighbors, 
FindClusters) and identifying the populations as described (19). In comparison, the first 50 principal com-
ponents (0.8 resolution) were used for visualization and clustering of  BALF data (24), and populations were 
identified by merging clusters based on expression of  FCN1, SPP1, and FABP4. The relative proportion of  
clusters between conditions was analyzed using Kruskal-Wallis test with Dunn’s correction (Prism v8.4.2).
Differential expression analysis. The Seurat FindAllMarkers function identified cluster markers in indi-
vidual data sets. The “test.use” function determined genes differentially expressed between clusters 
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within each data set using MAST. As recommended, for DE comparison the nonbatch normalized 
counts were used. Cluster markers must be expressed by ≥ 40% cells in the cluster (“min.pct” parameter 
0.4). Default values were used for all other parameters. Genes are considered significantly DE if  P < 
0.05 (Bonferroni correction, multiplied by number of  tests/clusters).
Ligand-receptor expression analysis. CellTalkDB (70) identified putative receptors of  mediators of  
interest (S100A12, SPP1, GAS6, and PROS1). An object containing all sequenced BALF cell types 
was prepared for visualization of  expression of  mediators and identified receptors by distinct BALF 
immune and epithelial clusters. The same quality control (QC) and integrative clustering procedure 
were followed as described above for analysis of  myeloid cells, without filtering cells for expression of  
CD14, MARCO, and LYZ. The first 30 principal components (0.3 resolution) were used for classifica-
tion of  BALF immune and epithelial cell types (24). Clusters were annotated by marker gene expres-
sion, and expression of  genes of  interest were visualized (FeaturePlot, RNA assay). Pseudobulk expres-
sion values of  genes of  interest were generated per sample, per cell type, and were exported for analysis 
(GraphPad Prism 9.1.0). A similar strategy was used to analyze SPP1 receptor expression in COVID-19 
blood (22), and data were obtained as a Seurat object with clustering and annotation as described above 
(individual clustering and dimensional reduction).
Data set comparison
Data set integration was performed as described above for 8993 common genes between ST and BALF. 
These “integrated” batch-corrected values were set as the default assay, and gene expression values are 
scaled before principal component analysis (PCA).
Clustering and dimensional reduction. To prevent bias in clustering, we matched BALF and ST cell num-
bers at 32,139 random cells. Data were rescaled (ScaleData), and the first 30 principal components were 
visualized by UMAP. Cells colored by original identity illustrated how clusters of  each data set overlay.
Comparative analyses. A count matrix with the average expression of  all common genes by each cluster 
was generated (AverageExpression) and hierarchical clustering (dist, hclust) performed. Data were visual-
ized by a dendrogram. PCA was performed on this pseudobulk expression matrix (prcomp). These anal-
yses identified similar clusters between BALF and ST. Shared marker genes between similar clusters were 
identified by Venny (2.1). To visualize pseudobulk expression of  overlapping marker genes, the pheatmap 
(1.0.12) package visualized shared genes as a heatmap using a custom script. Between–data set comparison 
of  pseudobulk of  expression marker genes (unique and common to all clusters) was performed by Pearson 
correlation (ggscatter, add = “reg.line”, conf.int = TRUE, cor.coef  = TRUE, cor.method = “pearson”) 
performed on the 916, the 721, and the 986 unique and common genes of  BALF FCN1+/ST CD48hi-
S100A12+, BALF FCN1+SPP1+/ST CD48+SPP1+, and BALF FABP4+/ST TREM2hi clusters, respectively.
Patients and clinical assessment
COVID-19 pneumonia patients. Reverse transcription PCR (RT-PCR) positive for SARS-CoV-2 by naso-
pharyngeal swab (NPS) were enrolled (COVID-Hospital, Fondazione Policlinico Universitario Agostino 
Gemelli, Rome, Italy). Each enrolled patient provided peripheral blood samples and COVID-19 sever-
ity was classified on hospital admission and/or before antiinflammatory treatment. Mild/moderate 
COVID-19 pneumonia was defined based on (mild) normal O2 saturation (>94%), or (moderate) abnormal 
O2 saturation (<94%); pneumonia based on imaging (chest x-ray or CT scan); and arterial oxygen partial 
pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2) PaO2/FiO2 (>200). Severe COVID-19 pneu-
monia was defined based on abnormal O2 saturation (<94%), presence of  pneumonia on imaging (x-ray 
or CT scan), and PaO2/FiO2 (≤200), or the use of  high-flow nasal cannula (HFNC), nonrebreather mask 
(NRB), bilevel positive airway pressure (BIPAP) or mechanical ventilation and vasopressor drugs use, cre-
atinine clearance greater than 30, and on alanine aminotransferase (ALT) less than 5× the upper limit of  
normal. Concomitant comorbidities including arterial hypertension, diabetes mellitus, ischemic cardiopa-
thy, COPD, dyslipidaemia, and cancer were recorded. The subsequent need and date of  ICU admission, 
intubation status, and O2 therapy for each patient was recorded. Patients were treated following the internal 
protocol defined by the Gemelli Against COVID-19 task force as described (35).
Convalescent post–COVID-19 patients. Follow-up outpatient attendance (Fondazione Policlinico Universi-
tario Agostino Gemelli) was offered to all discharged COVID-19 patients. Those recruited attended 68.6 ± 
4.4 days (mean ± SEM) after discharge and were RT-PCR–negative for SARS-CoV-2. They were assessed 
1 6
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e147413  https://doi.org/10.1172/jci.insight.147413
by a multidisciplinary team who collected demographic and clinical data, collected blood samples, and 
performed physical examinations. Persistence of  symptoms was recorded by a questionnaire.
Patients with community-acquired pneumonia. Patients with pneumonia, RT-PCR–negative for SARS-
CoV-2 by NPS, were enrolled at the Emergency Room (Fondazione Policlinico Universitario Agostino 
Gemelli). Demographic and clinical parameters were recorded, and blood samples were collected. These 
formed a comparison pathological control group for COVID-19 pneumonia. All patients and healthy con-
trol demographics and clinical characteristics are summarized in Supplemental Table 1.
Lung tissue IHC for SPP1+ macrophages. Postmortem lung tissue was obtained from COVID-19 pneumo-
nia (n = 2), bacterial pneumoniae (n = 3), H1N1 pneumonia (n = 3), and normal donors (n = 3). Demo-
graphic and clinical data are summarized in Supplemental Table 2. Autopsies were performed at the 
Department of  Woman and Child Health and Public Health, Institute of  Pathology of  The Fondazione 
Policlinico Universitario Agostino Gemelli, in accordance with the guidelines of  the Royal College of  
Pathologists (www.rcpath.org). Tissue collection was performed in accordance with appropriate protocols 
(71). Lung tissue was fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned at 4 mm, and 
stained as described (19). Briefly, after blocking (2 hours, 10% human serum, 10% of  goat serum, 1% BSA 
in TBS; Thermo Fisher Scientific) at room temperature, sections were incubated overnight at 4°C with the 
primary rabbit anti–human osteopontin (SPP1) antibody (Abcam, ab8448, 1:100) and mouse anti–human 
CD68 (Dako, clone PG-M1, 1:40) in blocking buffer above. Sections were washed twice (5 minutes, TBS 
plus 0.025% Triton X-100). Secondary antibody goat anti-rabbit IgG Alexa Fluor 488 (1:100), and goat 
anti–mouse IgG Alexa Fluor 660 (1:100) (both from Invitrogen) were incubated in dilution buffer (TBS 
with 1% BSA) and incubated for 1 hour at room temperature. Sections were washed 3 times for 5 minutes 
in TBS and counterstained with DAPI (H-1800-2/VECTASHIELD Vibrance Antifade Mounting Medium 
with DAPI), visualized with confocal microscopy with Zeiss Zen Black software. Negative controls were 
performed throughout using isotype matched antibodies.
SPP1, S100A12, GAS6, PROS1, IL-6, IL-8, IL-1β, and TNF-α ELISA. Blood samples were centrifuged 
(600g/15 minutes) and plasma aliquots were stored at –80°C until analysis by ELISA for SPP1 (BMS2066; 
Thermo Fisher Scientific), S100A12 (DY1052; R&D Systems), GAS6 (DY885B; R&D Systems), and 
PROS1 (NBP2-60585; NOVUS Biological). IL-6, IL-8, TNF-α and IL-1β plasma levels were quantified by 
single-plex ELISA (Multi-cytokine test for ELLA, Bio-Techne).
SPP1 stimulation of  whole blood for scRNAseq (BDRhapsody) analysis. Leukocytes were collected by 
centrifugation from heparinized blood samples (30 mL from 3 healthy donors) after RBC lysis (ACK 
Lysing Buffer, A1049201, Thermo Fischer Scientific). Leukocytes were plated at 5 × 106/well in a 
24-well cell-culture plate in 0.5 mL of  RPMI 1640 compete medium containing SPP1 (PeproTech, 120-
035) at concentrations of  0, 50, and 200 ng/mL. After 16 hours, cells were deattached (Accutase solu-
tion; A6964, Merck), transferred to U-bottom 96-well plates, and harvested by centrifugation at 200g 
for 4 minutes at 4°C. Cells from each donor/condition were labeled with unique Tags (below) using a 
Single-Cell Multiplexing Kit (BD Biosciences, 633781) for 20 minutes at room temperature according 
to manufacturer protocol.
Tag 1, ATTCAAGGGCAGCCGCGTCACGATTGGATACGACTGTTGGACCGG; Tag 2, 
TGGATGGGATAAGTGCGTGATGGACCGAAGGGACCTCGTGGCCGG; Tag 3, CGGCTCGT-
GCTGCGTCGTCTCAAGTCCAGAAACTCCGTGTATCCT; Tag 4, ATTGGGAGGCTTTCGTAC-
CGCTGCCGCCACCAGGTGATACCCGCT; Tag 5, CTCCCTGGTGTTCAATACCCGATGTGGTG-
GGCAGAATGTGGCTGG; Tag 6, TTACCCGCAGGAAGACGTATACCCCTCGTGCCAGGCGACCAATGC; 
Tag 7, TGTCTACGTCGGACCGCAAGAAGTGAGTCAGAGGCTGCACGCTGT; Tag 8, CCCCAC-
CAGGTTGCTTTGTCGGACGAGCCCGCACAGCGCTAGGAT; Tag 9, GTGATCCGCGCAGGCA-
CACATACCGACTCAGATGGGTTGTCCAGG.
Cells were washed ×3 with PBS, with centrifugation (200g for 4 minutes at 4°C), after which the 
tagged culture variants were pooled and loaded onto the scRNAseq BD Rhapsody Cartridge using the 
BD Rhapsody Cartridge Reagent Kit (catalog 633731) according to the manufacturer’s protocol. Sin-
gle-cell cDNA was prepared using the BD Rhapsody cDNA Kit (catalog 633773). This was followed by 
single-cell mRNA and tag-library preparation using BD Rhapsody Targeted mRNA and the Tag Ampli-
fication Kit (catalog 633774) and primers for the BD Rhapsody Immune Response Panel (399 genes; 
catalog 633750). Libraries were sequenced at a depth of  1,083,775 ± 236,302 (mean ± SEM) reads 
per tag using Illumina NextSeq 500 (Glasgow Polyomics). Then, 1535 ± 383 cells (mean ± SEM) per 
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tag were successfully sequenced. For analysis, the sequencing reads were processed with BD Genomics 
Rhapsody Analysis Pipeline CWL v.1.0 using the Seven Bridges platform. The Seurat package (3.1.5) 
in R was used to create an object from the RSEC_MolsPerCell.csv output file for each sample tag (Cre-
ateSeuratObject). Following the standard analysis protocol (19), normalization and data scaling were 
performed, followed by PCA of  the top 2000 variable genes (RunPCA). A UMAP plot (RunUMAP) 
was generated from the first 30 principal components. The same principal components were used to 
determine k-nearest neighbors for each cell during SNN graph construction, before clustering at a chosen 
resolution of  1.2 (FindNeighbors, FindClusters). Differential expression was performed (FindAllMark-
ers, test.use = MAST) to identify cluster markers and variable genes between SPP1 doses. Genes are 
considered significantly DE if  P < 0.05 with Bonferroni correction (Supplemental Data). To visualize 
heatmaps, the pheatmap (1.0.12) package was adapted. The normalized expression values were used to 
perform pseudobulk expression analysis of  each sample (AverageExpression). Raw data are accessible at 
EMBL-EBI (E-MTAB-10430). Using Seurat (AddModuleScore), we scored the clusters of  BDRhapsody 
COVID-19 whole-blood data set (22) based on average expression of  37 marker genes that characterized 
the SPP1-driven CD274+ neutrophil phenotype. A positive score suggests that this module of  genes is 
expressed more highly in a particular cell than expected across the general population, described in more 
detail in ref. 72. The module score was used to create a new assay for visualization and was illustrated 
using UMAP expression and pseudobulk sample expression heatmap.
Statistics
The scRNAseq data comparison is described in data comparison and pathway analysis. Statistical analysis 
of  patient clinical, demographic, and plasma cytokine levels were performed using SPSS V.20.0 (SPSS) and 
GraphPad Prism software version 9.0.0. Categorical and quantitative variables were described as frequen-
cies, percentage, median with the interquartile range, or mean ± SEM. Data on demographic and clinical 
parameters were compared between patients by Mann-Whitney U test or χ2 test, as appropriate. Cytokine 
concentrations between multiple patient groups and healthy donors were compared using 1-way ANOVA 
(or Kruskal-Wallis) with Dunn’s or Tukey’s correction for multiple comparisons, or 2-sided Mann-Whit-
ney U test for 2 groups. Cytokine categories at cut-off  level 108 ng/mL, 59 ng/mL, 24 ng/mL, and 15 
μg/mL for SPP1, S100A12, GAS6, and PROS1, respectively, were selected based on the median levels 
in all COVID-19 patients. Linear correlations between cytokines and continuous parameters were per-
formed using the Spearman’s rank test. Kaplan-Meyer analysis estimated the probability of  “no need to 
be transferred to ICU during hospitalization” for COVID-19 patients with acute pneumonia based on the 
previously determined cut-off  plasma values of  SPP1, S100A12, GAS6, and PROS1 at the time of  hospital 
admission. P < 0.05 was considered as statistically significant. Exact P values are provided on graphs.
Study approval
The study was approved by the Committee of  the Fondazione Policlinico Universitario Agostino Gemel-
li IRCCS — Università Cattolica del Sacro Cuore (nos. 12401/20 and 0024184/20) and University of  
Glasgow, MVLS College Ethical Committee (no. 2012073).
Author contributions
MKS oversaw the project and, with SA, interpreted clinical results and, with LM, interpreted computational 
and experimental results. MKS, LM, SA, and CM wrote the manuscript with feedback from all authors. LM 
analyzed and integrated 10X Genomics scRNAseq data and interpreted all computational data. SA and BT 
evaluated cytokine levels in patients’ samples and performed statistical analysis with clinical data integration. 
LM and MKS performed SPP1 stimulation of  whole blood and subsequent scRNAseq and data analysis. DS 
performed BD_Rhapsody sequencing library preparation and pathway analysis on scRNAseq data. LM ana-
lyzed BD_Rhapsody SPP1 data, and with DS mapped to COVID-19 data sets. TDO and MKS supervised all 
computational analysis in the study. BT, M. Sali, and M. Sanguinetti organized COVID-19 samples collection 
and handling and performed ELISA with ELLA technology. SP, AP, LP, A. Cingolani, RM, MF, MA, FL, 
FF, AG, A. Carfì, and EG provided clinical management of  patient cohorts during acute phase hospitaliza-
tion and at the postacute outpatient clinic and provided longitudinal clinical data. ES and VA provided lung 
tissues from cadavers and provided clinical data. AE assisted with ELISAs and preparation of  tissue samples. 
IBM and EG assisted with running the project. EG conceived the COVID-19 translational research activity 
1 8
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e147413  https://doi.org/10.1172/jci.insight.147413
for the “Immunology Core facility” of  the Fondazione Policlinico Universitario Agostino Gemelli IRCCS. 
Our study is a collaboration between 2 centers. The first 2 and last 2 authors contributed equally. With agree-
ment between all authors, and reflection on each author’s contribution, we alternated the first and last authors 
as listed to accurately reflect the collaborative effort of  the 2 centers.
Acknowledgments
We thank all the healthcare workers who are fighting SARS-CoV-2 on the front line, in particular the 
Gemelli Against-COVID-19 team and the COVID-19 Post-Acute Care team of  the Fondazione Policlinico 
Universitario A. Gemelli IRCCS, and all the patients who took part to the study. This work was supported 
by UKRI-MRC (grant no. MR/V036998/1 to SA, MKS, EG, TDO, CM, and IBM); the Research into 
Inflammatory Arthritis Centre Versus Arthritis UK (grant no. 22072) to LM, TDO, IBM, and MKS; Versus 
Arthritis UK project grant (no.22253) to MKS and AE; Linea D1 (Università Cattolica del Sacro Cuo-
re, no. R4124500654) to SA; Ricerca Finalizzata Ministero della Salute (no. GR-2018-12366992) to SA; 
Versus Arthritis UK Program grant (no. 21802) to MKS; Versus Arthritis UK project grant (no. 22272) to 
MKS; Wellcome Trust (no. 204820/Z/16/Z) to TDO and MKS; and BPF-Medical Research Trust to CM.
Address correspondence to: Mariola Kurowska-Stolarska or Thomas D. Otto, Research into Inflammatory 
Arthritis Centre Versus Arthritis (RACE), University of Glasgow, United Kingdom; 120 University Place, 
G12 8TA, Glasgow, United Kingdom. Phone: 44.141.330.6085; Email: mariola.kurowska-stolarska@glasgow.
ac.uk (MKS); Phone: 44.141.330.4698; Email: ThomasDan.Otto@glasgow.ac.uk (TDO). Or to: Elisa Grem-
ese, Institute of Internal Medicine and Geriatrics, Fondazione Policlinico Universitario Agostino Gemelli 
IRCCS, via Moscati 31, 00-168 Rome, Italy; Phone: 39.063.015.9876; Email: elisa.gremese@unicatt.it.
 1. Matacic C. Blood vessel injury may spur disease’s fatal second phase. Science. 2020;368(6495):1039–1040.
 2. Tay MZ, et al. The trinity of  COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374.
 3. Chua RL, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. 
Nat Biotechnol. 2020;38(8):970–979.
 4. Zhang Q, et al. Inborn errors of  type I IFN immunity in patients with life-threatening COVID-19. Science. 
2020;370(6515):eabd4570.
 5. Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 
2020;370(6515):eabd4585.
 6. Del Valle DM, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643.
 7. Silvin A, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 
2020;182(6):1401–1418.
 8. Chen L, et al. Elevated serum levels of  S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical out-
comes in COVID-19 patients. Cell Mol Immunol. 2020;17(9):992–994.
 9. Carvelli J, et al. Association of  COVID-19 inflammation with activation of  the C5a-C5aR1 axis. Nature. 2020;588(7836):146–150.
 10. Lucas C, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–469.
 11. Merrill JT, et al. Emerging evidence of  a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 
2020;16(10):581–589.
 12. Laing AG, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 
2020;26(10):1623–1635.
 13. Mathew D, et al. Deep immune profiling of  COVID-19 patients reveals distinct immunotypes with therapeutic implications. 
Science. 2020;369(6508):eabc8511.
 14. Pairo-Castineira E, et al. Genetic mechanisms of  critical illness in Covid-19. Nature. 2021;591(7848):92–98.
 15. Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2015;41(2):225–236.
 16. Alivernini S, et al. Comparative analysis of  synovial inflammation after SARS-CoV-2 infection [published online July 6, 2020]. 
Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218368.
 17. Yokogawa N, et al. Case of  acute arthritis following SARS-CoV-2 infection [published online June 26, 2020]. Ann Rheum Dis. 
https://doi.org/10.1136/annrheumdis-2020-218281.
 18. Firestein GS, McInnes IB. Immunopathogenesis of  rheumatoid arthritis. Immunity. 2017;46(2):183–196.
 19. Alivernini S, et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat 
Med. 2020;26(8):1295–1306.
 20. Zhu L, et al. Single-cell sequencing of  peripheral mononuclear cells reveals distinct immune response landscapes of  COVID-19 
and influenza patients. Immunity. 2020;53(3):685–696.
 21. Zhang JY, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21(9):1107–1118.
 22. Schulte-Schrepping J, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182(6):1419–1440.
 23. Guo C, et al. Single-cell analysis of  two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding 
cytokine storm. Nat Commun. 2020;11(1):3924.
 24. Liao M, et al. Single-cell landscape of  bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844.
 25. Xu G, et al. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. 
1 9
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e147413  https://doi.org/10.1172/jci.insight.147413
Cell Discov. 2020;6:73.
 26. Carfi A, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605.
 27. Misharin AV, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp 
Med. 2017;214(8):2387–2404.
 28. Chakarov S, et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science. 
2019;363(6432):eaau0964.
 29. Gibbings SL, et al. Three unique interstitial macrophages in the murine lung at steady state. Am J Respir Cell Mol Biol. 
2017;57(1):66–76.
 30. Aran D, et al. Reference-based analysis of  lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immu-
nol. 2019;20(2):163–172.
 31. Ural BB, et al. Identification of  a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and 
immunoregulatory properties. Sci Immunol. 2020;5(45):eaax8756.
 32. Reyfman PA, et al. Single-cell transcriptomic analysis of  human lung provides insights into the pathobiology of  pulmonary 
fibrosis. Am J Respir Crit Care Med. 2019;199(12):1517–1536.
 33. Morales-Nebreda L, et al. The heterogeneity of  lung macrophages in the susceptibility to disease. Eur Respir Rev. 
2015;24(137):505–509.
 34. Mirastschijski U, et al. Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia. Front Med 
(Lausanne). 2020;7:254.
 35. Gremese E, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020;27:100553.
 36. Wise J. Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report. 
BMJ. 2020;371:m4530.
 37. Stuart T, et al. Comprehensive integration of  single-cell data. Cell. 2019;177(7):1888–1902.
 38. Campbell CM. The opening salvo of  anti-complement therapy against COVID-19. Lancet Rheumatol. 2020;2(12):e729–e730.
 39. Kahles F, et al. Osteopontin: a novel regulator at the cross roads of  inflammation, obesity and diabetes. Mol Metab. 
2014;3(4):384–393.
 40. Nolting J, et al. Retinoic acid can enhance conversion of  naive into regulatory T cells independently of  secreted cytokines. J Exp 
Med. 2009;206(10):2131–2139.
 41. Vogt L, et al. VSIG4, a B7 family-related protein, is a negative regulator of  T cell activation. J Clin Invest. 2006;116(10):2817–2826.
 42. Rothlin CV, et al. TAM receptors are pleiotropic inhibitors of  the innate immune response. Cell. 2007;131(6):1124–1136.
 43. Nagata K, et al. Identification of  the product of  growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer recep-
tor tyrosine kinases. J Biol Chem. 1996;271(47):30022–30027.
 44. Lew ED, et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife. 2014;3:e03385.
 45. Lemke G, Silverman GJ. Blood clots and TAM receptor signalling in COVID-19 pathogenesis. Nat Rev Immunol. 
2020;20(7):395–396.
 46. Schmid ET, et al. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. Elife. 2016;5:e12414.
 47. Fujimori T, et al. The Axl receptor tyrosine kinase is a discriminator of  macrophage function in the inflamed lung. Mucosal 
Immunol. 2015;8(5):1021–1030.
 48. Lemke G. Biology of  the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5(11):a009076.
 49. Liu J, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. 
J Transl Med. 2020;18(1):206.
 50. van der Meer JH, et al. TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood. 2014;123(16):2460–2469.
 51. Skendros P, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immuno-
thrombosis. J Clin Invest. 2020;130(11):6151–6157.
 52. Radermecker C, et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe 
COVID-19. J Exp Med. 2020;217(12):e20201012.
 53. Pandolfi L, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. BMC Pulm Med. 
2020;20(1):301.
 54. Zeng HL, et al. Proteomic characteristics of  bronchoalveolar lavage fluid in critical COVID-19 patients [published online Octo-
ber 24, 2020]. FEBS J. https://doi.org/10.1111/febs.15609.
 55. Morse C, et al. Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J. 
2019;54(2):1802441.
 56. Wen W, et al. Immune cell profiling of  COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6(1):31.
 57. Scott NA, et al. Recovery of  monocyte exhaustion is associated with resolution of  lung injury in COVID-19 convalescence 
[preprint]. https://doi.org/10.1101/2020.10.10.20207449. Posted on medRxiv October 16, 2020.
 58. Kurowska-Stolarska M, Alivernini S. Synovial tissue macrophages: friend or foe? RMD Open. 2017;3(2):e000527.
 59. Zagorska A, et al. Diversification of  TAM receptor tyrosine kinase function. Nat Immunol. 2014;15(10):920–928.
 60. Gautier EL, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of  
mouse tissue macrophages. Nat Immunol. 2012;13(11):1118–1128.
 61. Waterborg CEJ, et al. Protective role of  the MER tyrosine kinase via efferocytosis in rheumatoid arthritis models. Front Immu-
nol. 2018;9:742.
 62. Schwartzberg PL. Immunology. Tampering with the immune system. Science. 2001;293(5528):228–229.
 63. McGonagle D, et al. Mechanistic immunological based classification of  rheumatoid arthritis. Autoimmun Rev. 
2018;17(11):1115–1123.
 64. Schett G, et al. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272.
 65. Lang FM, et al. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat Rev Immunol. 
2020;20(8):507–514.
 66. Xu X, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975.
 67. De Luca G, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a 
2 0
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e147413  https://doi.org/10.1172/jci.insight.147413
single-centre, prospective cohort study. Lancet Rheumatol. 2020;2(8):465–473.
 68. Group RC, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020;384(8):693–704.
 69. Bronte V, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 
2020;130(12):6409–6416.
 70. Shao X, et al. CellTalkDB: a manually curated database of  ligand-receptor interactions in humans and mice. Brief  Bioinform. 
2020;bbaa269.
 71. Aquila I, et al. Severe acute respiratory syndrome Coronavirus 2 pandemic. Arch Pathol Lab Med. 2020;144(9):1048–1056.
 72. Tirosh I, et al. Dissecting the multicellular ecosystem of  metastatic melanoma by single-cell RNA-seq. Science. 
2016;352(6282):189–196.
